Growth Strategy
We turn your growth number into six to eight tested bets, each with a market, a technology and a way to win.
Learn moreGrowth strategy · Due diligence · IP consulting
Rapid Alpha is a growth advisory firm for technical companies from $25M to $150M, many of them PE-backed. In sixteen weeks we find where the growth in your plan actually comes from, run measured experiments and turn it into momentum your team can accelerate.
Three client exitsone company exited twice in 90 days
$20M Series Ato take existing technology into new markets
Seven-figure collaborationand investment, for a US market entry
2 acquisitions closed. 1 offer withdrawn.IMDEX’s build-or-buy research ran through to the deals. We did the work a corporate development team would do.
12 R&D programs valuedFor BHP, every program weighed on relative value, with partners found for the ones worth backing and terms negotiated.
Interviews to a signed term sheetOne client's customer interviews became a signed term sheet, a field trial and a grant strategy.
Ten years ago, a company needed about 5% growth a year, a 5% compound annual growth rate (CAGR), to meet its investors' expectations. Today it needs a 10 to 12% CAGR.
Yet most growth plans are still built from market reports, benchmarks and last year's results. Those show where you've been. They don't show which new products, customers or markets will bring in next year's revenue, or how confident you can be in them. That's the gap we close.
We work in two ways. Some clients want advice: growth strategy and intellectual property consulting. Others want us to act as the corporate development and IP team they haven't built yet. Most use us for both. Other firms call this growth and innovation consulting; we describe it by what you get.
We turn your growth number into six to eight tested bets, each with a market, a technology and a way to win.
Learn moreTechnology and IP evidence on a target, inside the deal window: asset purchases, acqui-hires and full company acquisitions.
Learn moreWe read your patents for what they're worth to growth, not just whether they're valid, and build an IP program that supports the plan.
Learn moreWe see the growth your patents make possible, and the risks in them.
Most advisors stop at the recommendation. We have carried a technology from first customer interviews to a signed term sheet and field trial.
Our platform, EVOS, gathers and organizes the evidence. Our people extract insights to help you make the right decision for your firm.
We map the technologies, patents and markets around your business.
We test which markets are real, how big they are and who else is there.
We talk to customers and run measured experiments.
You get six to eight scored bets and a clear call on each: advance, hold or stop.
Twelve programs to weigh the relative value of R&D efforts, identify strategic partners, and negotiate collaboration and field-trial agreements for technology access.
Read the case
A $20M Series A. XTEND took technology it already had into new markets, and its growth plan held up in front of investors.
Read the caseCommercialized valuable IP through patent sales and exclusive field-of-use licensing, backed by an internal tool for tracking where Boeing wants to transact.
Read the caseFrom customer interviews to a signed term sheet. We tested a new application with real buyers, then stayed through the deal: term sheet, field trial and grant strategy.
Read the caseAs we quickly commercialize our best ideas globally, Rapid Alpha continues to be an ideal business partner, brokering introductions with potential partners so we can immediately realize real commercial value.
You know you need to grow, but not where. Too many ideas, no clear way to choose between them.
You know where, but not how. The market is clear, but you lack the technology, IP or team to get there.
Our four-minute diagnostic scores both and shows which one is holding you back.
Bring one company. In a one-hour working session we'll look at your growth number together, and you'll leave knowing whether we can help.